The FDA has approved Attruby, a new oral treatment that helps reduce heart-related deaths and hospital visits among adults ...

BridgeBio Pharma, Inc. BBIO recently announced that it obtained FDA approval for its pipeline candidate acoramidis for the ...

The stock market responded positively to the company's announcement, with its share price leaping more than 28% following the ...

The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...

BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...

Ultromics Ltd. received clearance from the U.S. FDA for Echogo Amyloidosis, its artificial intelligence-enhanced software ...

Patients with cardiac amyloidosis have very poor survival without ... Conventional heart failure drugs are usually not well tolerated and the long-term benefits are unclear. Cardiac ...

At our Cardiac Amyloidosis Clinic, people with a diagnosis of cardiac amyloidosis receive treatment from a team of experts. If you have related symptoms such as swelling of the ankles and legs ...

Definite diagnosis is based on endomyocardial biopsy and treatment of cardiac amyloidosis is a challenge. Heart transplantation, although controversial, has demonstrated survival benefit.

Your healthcare provider will likely prescribe you medications to treat your symptoms and help lower the risk of complications. There are two main types of cardiac amyloidosis: light chain ...

Diagnosis and treatment may be challenging at first because the symptoms and causes vary between different types of amyloidosis. They may also mimic other conditions, such as heart disease.